, Singapore

Here's what buoyed biomedical output in June

The sector managed to hit an 18.3% surge in production.

After two consecutive double-digit declines, Singapore's biomedical manufacturing output posted an 18.3% growth in June. 

According to RHB, this is due to the 21.4% expansion in the pharmaceutical output, an improvement from the 36.1% decline in the preceding month.

"This was on account of the higher production of active pharmaceutical ingredients and biological products," RHB noted.

The cluster would have posted an even higher growth if it were not for the medical technology segment, capping some of the upsides.

To recall, Singapore industrial output jumped 12.1%, accelerating from 4.4% growth in the preceding month. Excluding biomedical manufacturing, the IPI grew 11.9% YoY in June, easing slightly from a 13.1% reading in the month before.
 

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.


The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.


So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Top News

Why deep banking needs a new local fix in every market
Regulation and customer maturity vary by country as do credit and interest rate cycles, Monzo’s TS Anil says.
MAS clears Ebury Singapore to add currency hedging, e-money services
Ebury is a global fintech firm specialising in cross-border payments, amongst others.
Payment firms call for regulatory alignment as cross-border links expand
Bilateral and multilateral payment links could improve network coverage and resilience across markets.